Glioblastoma‐associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties

Glioblastoma (GB) displays diffusely infiltrative growth patterns. Dispersive cells escape surgical resection and contribute to tumour recurrence within a few centimeters of the resection cavity in 90% of cases. We know that the non‐neoplastic stromal compartment, in addition to infiltrative tumour cells, plays an active role in tumour recurrence. We isolated a new stromal cell population from the histologically normal surgical margins of GB by computer‐guided stereotaxic biopsies and primary culture. These GB‐associated stromal cells (GASCs) share phenotypic and functional properties with the cancer‐associated fibroblasts (CAFs) described in the stroma of carcinomas. In particular, GASCs have tumour‐promoting effects on glioma cells in vitro and in vivo. Here, we describe a quantitative proteomic analysis, using iTRAQ labelling and mass spectrometry, to compare GASCs with control stromal cells derived from non‐GB peripheral brain tissues. A total of 1077 proteins were quantified and 67 proteins were found to differ between GASCs and control stromal cells. Several proteins changed in GASCs are related to a highly motile myofibroblast phenotype, and to wound healing and angiogenesis. The results for several selected proteins were validated by western blotting or flow cytometry. Furthermore, the effect of GASCs on angiogenesis was confirmed using the orthotopic U87MG glioma model. In conclusion, GASCs, isolated from GB histologically normal surgical margins and found mostly near blood vessels, could be a vascular niche constituent establishing a permissive environment, facilitating angiogenesis and possibly colonization of recurrence‐initiating cells. We identify various proteins as being expressed in GASCs: some of these proteins may serve as prognostic factors for GB and/or targets for anti‐glioma treatment. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd

[1]  K. Camphausen,et al.  Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. , 2005, Cancer research.

[2]  D. Berney,et al.  Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib , 2011, Oncogene.

[3]  L. Ellis,et al.  19.3 n&v MH IF , 2009 .

[4]  Hui Wang,et al.  Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. , 2010, Cancer research.

[5]  Kevin Petrecca,et al.  Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma , 2012, Journal of Neuro-Oncology.

[6]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[7]  Q. Ding,et al.  Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma , 2012, Oncology letters.

[8]  A. Omuro.  Exploring multi-targeting strategies for the treatment of gliomas. , 2008, Current opinion in investigational drugs.

[9]  E. Gamelin,et al.  Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation , 2008, Proteome Science.

[10]  Tom T. Chen,et al.  ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1 , 2012, Nature Medicine.

[11]  Xiandong Lin,et al.  Overexpression of thrombospondin‐1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma , 2012, Journal of surgical oncology.

[12]  B. Rosen,et al.  Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation , 2013, Proceedings of the National Academy of Sciences.

[13]  I. Christensen,et al.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. , 1983, Cytometry.

[14]  T. Taxt,et al.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[15]  C. James,et al.  Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion , 2012, Molecular Cancer.

[16]  P. Schiller,et al.  Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. , 2010, Biomaterials.

[17]  J. A. van der Laak,et al.  Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2 , 2013, PloS one.

[18]  M. Grigorian,et al.  Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. , 2012, Neoplasia.

[19]  J. Dedman,et al.  Annexins II and V inhibit cell migration. , 1997, Experimental cell research.

[20]  E. Wawrousek,et al.  alphaB-crystallin regulation of angiogenesis by modulation of VEGF. , 2010, Blood.

[21]  H. Dvorak,et al.  Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. , 2012, Cancer research.

[22]  J. Kros,et al.  A crucial role of caldesmon in vascular development in vivo. , 2008, Cardiovascular research.

[23]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[24]  Tracy T Batchelor,et al.  Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. , 2011, Cancer research.

[25]  Michal Neeman,et al.  In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. , 2007, Cancer research.

[26]  H. Koyama,et al.  Loss of smooth muscle calponin results in impaired blood vessel maturation in the tumor–host microenvironment , 2007, Cancer science.

[27]  A. Aboussekhra,et al.  Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic , 2013, The Journal of pathology.

[28]  G. Bergers,et al.  Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. , 2013, CNS oncology.

[29]  Shalom Madar,et al.  'Cancer associated fibroblasts'--more than meets the eye. , 2013, Trends in molecular medicine.

[30]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[31]  D. Cheresh,et al.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.

[32]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[33]  P. Malfertheiner,et al.  Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density , 2001, Virchows Archiv.

[34]  Thomas D. Pollard,et al.  Actin, a Central Player in Cell Shape and Movement , 2009, Science.

[35]  G. Maira,et al.  The influence of surgery on recurrence pattern of glioblastoma , 2013, Clinical Neurology and Neurosurgery.

[36]  A. Orimo,et al.  Carcinoma‐associated fibroblasts: Non‐neoplastic tumour‐promoting mesenchymal cells , 2013, Journal of cellular physiology.

[37]  J. McCarty.  Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET? , 2013, Clinical Cancer Research.

[38]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[39]  S. Takano.  Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation , 2012, Brain Tumor Pathology.

[40]  J. Bruna,et al.  Bevacizumab for the Treatment of Glioblastoma , 2013, Clinical Medicine Insights. Oncology.

[41]  V. Shah,et al.  Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth. , 2010, The American journal of pathology.

[42]  John N. Weinstein,et al.  High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID) , 2005, BMC Bioinformatics.

[43]  N. Erez,et al.  From sentinel cells to inflammatory culprits: cancer‐associated fibroblasts in tumour‐related inflammation , 2013, The Journal of pathology.

[44]  Herbert J Zeh,et al.  High-mobility group box 1 and cancer. , 2010, Biochimica et biophysica acta.

[45]  T. Tokuyasu,et al.  Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance , 2013, Clinical Cancer Research.

[46]  Scott D. Hansen,et al.  In vitro studies of actin filament and network dynamics. , 2013, Current opinion in cell biology.

[47]  P. A. Futreal,et al.  Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. , 2010, Cancer research.

[48]  W A Buurman,et al.  Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1 , 2013, Oncogene.

[49]  H. Immervoll,et al.  Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma , 2011, PloS one.

[50]  L. Claesson‐Welsh,et al.  alphaB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. , 2008, Blood.

[51]  J. Mosser,et al.  Isolation of a new cell population in the glioblastoma microenvironment , 2012, Journal of Neuro-Oncology.

[52]  W. Jiang,et al.  αB-Crystallin, an Effector of Unfolded Protein Response, Confers Anti-VEGF Resistance to Breast Cancer via Maintenance of Intracrine VEGF in Endothelial Cells , 2011, Molecular Cancer Research.

[53]  B. Geiger,et al.  Environmental sensing through focal adhesions , 2009, Nature Reviews Molecular Cell Biology.